Overview

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose inhaler (MDI) (GFF; PT003), GP MDI (PT001), and FF MDI (PT005) compared with Placebo MDI in subjects with moderate to very severe COPD.

Phase:

Phase 3

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Formoterol Fumarate
Glycopyrrolate